Pharmacoscintigraphic Evaluation and Safety of a Novel, Dual-pulse, Delayed-release carbidopa/levodopa Tablet for Bedtime Dosing
Objective: To characterize the pharmacokinetics (PK) of carbidopa (CD) and levodopa (LD) from delayed-release (DR) tablets intended for bedtime administration and to correlate systemic exposure…Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Provides Sustained Improvement In Quality Of Life In Advanced Parkinson’s For Up To Two Years
Objective: To describe changes in health-related quality of life (QoL), assessed using the 8-item Parkinson’s Disease Questionnaire (PDQ-8), in people with advanced Parkinson’s disease (aPD)…Beyond Motor Fluctuations: Non-Motor and Quality-Of-Life Outcomes with Subcutaneous Foslevodopa/Foscarbidopa Infusion in Real-World Practice
Objective: To evaluate motor and non-motor outcomes, including sleep disturbances, of continuous subcutaneous foslevodopa/foscarbidopa infusion in a heterogeneous real-world cohort of patients with advanced Parkinson’s…Dopaminergic Medication Changes Following LFP-Guided Deep Brain Stimulation Programming in Parkinson’s Disease: A Single-Centre Audit
Objective: To evaluate changes in levodopa equivalent daily dose (LEDD) following deep brain stimulation (DBS) with local field potential (LFP)-guided programming in patients with Parkinson’s disease.…Switching to IPX203 from IPX066 Significantly Improves “Good On” Time and Reduces Motor Fluctuations Under Real-World Conditions
Objective: To evaluate the change in daily “Good On” time and motor fluctuations during conversion of patients from IPX066 to IPX203 as an interim analysis…Subcutaneous Levodopa Infusion in Multiple System Atrophy: a Case Series
Objective: To describe safety, tolerability and clinical response to continuous subcutaneous (SC) levodopa infusion in three patients with multiple system atrophy (MSA). Background: Response to…Tremor-onset Parkinson’s Disease: Does Leg Tremor Portend a Poor Prognosis?
Objective: This study aims to assess the prognosis of baseline leg tremor-onset in autopsy-verified Parkinson’s Disease (PD) patients. Background: PD is a chronic neurological condition with a multifactorial etiology composed…Personalised Selection Of Device-Aided Infusion Therapies In Advanced Parkinson’s Disease: A European Expert Delphi Consensus
Objective: To develop an expert consensus on personalised treatment selection in advanced Parkinson’s disease (aPD) patients who are considered suitable for transition to device-aided therapies…Use of Mucuna Pruriens (M. Pruriens) in People with Parkinson’s Disease (PwPD)
Objective: To characterize M. pruriens use among local (primarily Argentinian) PwPD. Background: M. pruriens is a leguminous plant used in Ayurvedic medicine to treat Parkinsonism…Evaluating the Conversion of Immediate-Release and/or Extended-Release Levodopa to IPX203 in Patients with Parkinson’s Disease
Objective: This quality improvement (QI) project was conducted to evaluate the impact of the conversion from immediate-release (IR) and/or extended-release (ER) levodopa (LD) to mucoadhesive polymer…
- 1
- 2
- 3
- …
- 70
- Next Page »